Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 9:20 a.m. ET.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00 per share before underwriting discounts and commissions, which included the exercise in full by the underwriters of their option to purchase 806,250 additional shares of KalVista’s common stock. After giving effect to the full exercise of the over-allotment option to purchase additional shares, the...
KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising $193.5 million in gross proceeds. Earlier, the company offered 4.5 million shares. The offer price represents a marginal discount of 4% on the last close price of $37.46. Underwriters have an option to purchase up to an additional 806,250 shares. Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co. are acting as the joint book-runn...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be $193.5 million. In addition, KalVista has granted the underwriters a 30-day option to purchase up to an additional 806,250...
Can this under-the-radar biotech and its hereditary angioedema candidate produce more gains for investors?
Shares of KalVista Pharmaceuticals (NASDAQ: KALV) soared 115% on Tuesday after the pharmaceutical company released promising results from its phase 2 clinical trial for KVD900, its oral drug for hereditary angioedema (HAE) attacks. KalVista's study showed that 15% of the patients who were treated with KVD900 within one hour of experiencing a swelling attack required rescue medication, compared to 30% of those who received a placebo. KalVista CEO Andrew Crockett said KVD900 is the first oral dr...
KalVista Pharmaceuticals reported "overwhelmingly positive" results for its hereditary angioedema study on Tuesday, and the biotech stock touched a five-year high.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announced today that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten public offering. In addition, KalVista intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock offered in the public offering at the public offering price less underwriting discounts and commissions. All of the shares will be offered and sold by KalVista. The offering is subject to mark...